Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts V. S. PokrovskyN. Yu AnisimovaI. V. Manukhov PRECLINICAL STUDIES 15 June 2018 Pages: 201 - 209
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2 Tomoko Takimoto-ShimomuraTaku TsukamotoJunya Kuroda PRECLINICAL STUDIES 21 June 2018 Pages: 210 - 222
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells Viviane A. O. SilvaMarcela N. RosaRui Manuel Reis PRECLINICAL STUDIES 22 June 2018 Pages: 223 - 237
Alteration of benzo(a)pyrene biotransformation by resveratrol in ApcMin/+ mouse model of colon carcinogenesis Ashley C. HudersonP. V. Rekha DeviAramandla Ramesh PRECLINICAL STUDIES 22 June 2018 Pages: 238 - 251
Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types Cijo George VazhappillyEkram SalehRaafat El-Awady PRECLINICAL STUDIES 27 June 2018 Pages: 252 - 261
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines Esther Amalia GuzmánTara Peterson PittsAmy Elizabeth Wright PRECLINICAL STUDIES 12 July 2018 Pages: 262 - 270
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor James J. HardingTodd M. BauerDejan Juric PHASE I STUDIES Open access 03 August 2018 Pages: 271 - 281
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor Ciara M. KellyAlexander N. ShoushtariWilliam D. Tap PHASE I STUDIES 13 August 2018 Pages: 282 - 290
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer Yusuke ChiharaKoji DateKoichi Takayama PHASE I STUDIES 18 August 2018 Pages: 291 - 296
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Tycel PhillipsPaul M. BarrDavid C. Smith PHASE I STUDIES Open access 22 August 2018 Pages: 297 - 306
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors Khalid JaziehJulian MolinaAlex Adjei PHASE I STUDIES 31 August 2018 Pages: 307 - 314
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer Laura W. GoffNilofer S. AzadJordan D. Berlin PHASE I STUDIES 06 September 2018 Pages: 315 - 322
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma Melissa A. ReimersMaryann M. ShangoAjjai S. Alva PHASE II STUDIES 05 November 2018 Pages: 323 - 330
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer Pedro C. BarataMatthew CooneyJorge A. Garcia PHASE II STUDIES 07 November 2018 Pages: 331 - 337
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer Kei SaitoHiroyuki IsayamaKazuhiko Koike PHASE II STUDIES 09 November 2018 Pages: 338 - 344
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study Clinton YamFrancisco J. EstevaVicente Valero PHASE II STUDIES 05 January 2019 Pages: 345 - 351
IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study Tao LvYujie WangXiaoshen Wang PHASE II STUDIES 08 January 2019 Pages: 352 - 359
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib Francesco FacchinettiLetizia GnettiMarcello Tiseo SHORT REPORT 01 August 2018 Pages: 360 - 363
Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model Weijing CaiRanjala RatnayakeHendrik Luesch SHORT REPORT 03 August 2018 Pages: 364 - 374
Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma Charlée NardinSophie BorotFrançois Aubin SHORT REPORT 25 August 2018 Pages: 375 - 377
Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity Lisa M. OppegardJustine L. DelgadoHiroshi Hiasa SHORT REPORT 10 September 2018 Pages: 378 - 383
Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor Yuan LuAng LiXinling Ren SHORT REPORT 10 September 2018 Pages: 384 - 400